Payment overview · 2025
General Payments
$16.18
1 reported records · 1 companies
Healthcare provider profile · identity verified
David M Muhs, MD
Allopathic & Osteopathic Physicians|Family Medicine · JAMESTOWN, ND · NPI 1114945797
Verified facts
What the public records show
CMS Open Payments records show David M Muhs, MD received $16.18 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.18 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $16.18 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1112 | 233 |
| Lisinopril | Lisinopril | 631 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 514 | 135 |
| Furosemide | Furosemide | 363 | 81 |
| Omeprazole | Omeprazole | 361 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 348 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 325 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 65 |
| Metformin Hcl | Metformin Hcl | 291 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 276 | 67 |
| Losartan Potassium | Losartan Potassium | 241 | 66 |
| Carvedilol | Carvedilol | 237 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 231 | 62 |
| Gabapentin | Gabapentin | 213 | 51 |
| Simvastatin | Simvastatin | 211 | 48 |
| Jardiance | Empagliflozin | 199 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 181 | 31 |
| Eliquis | Apixaban | 175 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 170 | 38 |
| Ozempic | Semaglutide | 156 | 22 |
| Allopurinol | Allopurinol | 154 | 44 |
| Metformin Hcl Er | Metformin Hcl | 151 | 33 |
| Finasteride | Finasteride | 147 | 34 |
| Spironolactone | Spironolactone | 141 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 37 |
| Potassium Chloride | Potassium Chloride | 132 | 33 |
| Xarelto | Rivaroxaban | 130 | 18 |
| Klor-Con M10 | Potassium Chloride | 123 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 43 |
| Sertraline Hcl | Sertraline Hcl | 115 | 23 |
| Alprazolam | Alprazolam | 105 | 21 |
| Warfarin Sodium | Warfarin Sodium | 105 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 101 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 99 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 27 |
| Tramadol Hcl | Tramadol Hcl | 93 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 18 |
| Terazosin Hcl | Terazosin Hcl | 88 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 37 |
| Jantoven | Warfarin Sodium | 83 | 19 |
| Chlorthalidone | Chlorthalidone | 82 | 19 |
| Divalproex Sodium | Divalproex Sodium | 82 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 82 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 20 |
| Klor-Con M20 | Potassium Chloride | 78 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 77 | 12 |
| Trazodone Hcl | Trazodone Hcl | 75 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 67 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 15 |
| Prednisone | Prednisone | 64 | 27 |
| Donepezil Hcl | Donepezil Hcl | 63 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 15 |
| Bupropion Xl | Bupropion Hcl | 60 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 21 |
| Latanoprost | Latanoprost | 59 | 12 |
| Montelukast Sodium | Montelukast Sodium | 59 | 14 |
| Nitroglycerin | Nitroglycerin | 57 | 38 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 56 | suppressed |
| Lorazepam | Lorazepam | 56 | 25 |
| Trulicity | Dulaglutide | 55 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 26 |
| Digoxin | Digoxin | 47 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 13 |
| Alendronate Sodium | Alendronate Sodium | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Calcitriol | Calcitriol | 37 | 12 |
| Cephalexin | Cephalexin | 37 | 28 |
| Topiramate | Topiramate | 35 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Ketoconazole | Ketoconazole | 33 | 26 |
| Olanzapine | Olanzapine | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Celecoxib | Celecoxib | 31 | 12 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Meloxicam | Meloxicam | 30 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Risperidone | Risperidone | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 23 | 16 |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Procto-Med Hc | Hydrocortisone | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Darunavir | Darunavir | 12 | suppressed |
| Isentress | Raltegravir Potassium | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Ritonavir | Ritonavir | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.18 · 1 records | ABBVIE INC. | QULIPTA, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error